Tag: P2y12

Up to 30% of patients show an inadequate response to standard clopidogrel (Plavix) therapy, a phenomenon known as high on-treatment platelet reactivity. Understanding what **P2Y12 should be on Plavix** is crucial for patients undergoing antiplatelet therapy after cardiovascular events, as it can significantly impact clinical outcomes.

In the PLATO trial, ticagrelor (Brilinta) demonstrated a significant 16% relative reduction in the composite primary endpoint of cardiovascular death, myocardial infarction, and stroke compared with clopidogrel. This clinical success is rooted in its unique mechanism of action, which explains precisely how **does brilinta affect P2Y12?**